Monjuvi (Tafasitamab-cxix)
- Medicine Name: Monjuvi
- Generic Name: Tafasitamab-cxix
- Dosage Form & Strength: Injection: 200 mg as Lyophilized Powder in Single Dose Vial for Reconstitution
- Manufactured By: Morphosys US Inc.
Medical Uses
Monjuvi is a CD19-directed cytolytic antibody used in combination with lenalidomide to treat adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT).
Recommended Dosage: The recommended dosage is 12 mg/kg as an intravenous infusion as per the following dosing schedule:
- Cycle 1: Days 1’st, 4’th, 8’th, 15’th and 22’nd of the 28-day cycle.
- Cycles 2 and 3: Days 1’st, 8’th, 15’th and 22’nd of each 28-day cycle.
- Cycle 4 and beyond: Days 1’st and 15’th of each 28-day cycle.
Administer Monjuvi in combination with lenalidomide for a maximum of 12 cycles and then continue this medicine as monotherapy until the disease is progressive or in case of unacceptable toxicity.
Warning & Precautions
- The monjuvi 200 mg can cause infusion-related reactions. Premedicate patients prior to initiating monjuvi infusion. Assess patients frequently during infusion.
- Tafasitamab-cxix can cause serious/severe myelosuppression, including thrombocytopenia, neutropenia, and anemia. Monitor CBC before each treatment cycle and throughout therapy. Evaluate patients with neutropenia for signs of infection.
- Fatal and serious infections, including opportunistic infections, appeared in patients while on treatment with monjuvi injection and after the final dose. Assess patients for signs and symptoms of infection and manage as appropriate.
- Based on its working, Tafasitamab-cxix may cause fetal B-cell depletion if administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive age to use apt contraception during treatment and for at least 3 months after the final dose.
Documentation & Availability
What documents are required to import MONJUVI to India?
MONJUVI (tafasitamab-cxix) can be imported by patients or government hospitals on the name of the patients only.
The following documentation is required to import the product:
- A valid prescription from a qualified doctor.
- Patient’s diagnostic reports.
- Patient’s ID proof (issued by the Government of India).
How is the order confirmed?
The order will be confirmed only after the receipt of:
- A valid prescription from a doctor.
- Import permit if applicable.
Is MONJUVI available in India?
MONJUVI (Tafasitamab-cxix Injection) is a (prescription drug, prescription medication or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.
IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is facilitator providing input
- On availability in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore and Pune etc.)
- Medicine Price.
- Finding Genuine and reliable source from Canada, Europe, USA and AustraliaEnsuring 100% transparency.
MONJUVI (Tafasitamab-cxix 200 mg injection) can be made available to patients, doctors and hospitals at Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow and Pune and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and import permit.
IPN (Indian Pharma Network) can facilitate the supply of MONJUVI (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable)
Please contact +91-9310090915 | Toll-Free No: 1800-889-1064 or write us at info@indianpharmanetwork.in for monjuvi price in India.
We take guarantee of quality and delivery anywhere in the world as per the buyer’s requirements.
Sourcing & Delivery
Indian Pharma Network is able to source MONJUVI (Cancer Treatment Medicines) from across the globe, and has the ability to supply. Indian Pharma offers its customers worldwide access to the best available treatment.
Indian Pharma Network is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.
FAQ
What is the Generic Name for the trade name drug Monjuvi®?
Tafasitamab-cxix is Generic Name for the trade name drug Monjuvi®.
What is the Manufacturer Name of Monjuvi®?
Monjuvi® is manufactured by Morphosys US Inc.
Is Monjuvi® approved by the FDA?
Yes, Monjuvi® is approved by the FDA. Date of approval: July 31, 2020.
What is Monjuvi®?
It is a prescription medication given with lenalidomide to treat adult patients with certain types of diffuse large B-cell lymphoma (DLBCL) that has come back (relapsed) or that did not respond to previous treatment (refractory) and who are not eligible for stem cell transplant.
What is the dosage and form of Monjuvi® supplied?
Monjuvi is supplied for injection: 200 mg of tafasitamab-cxix as lyophilized powder in a single-dose vial for reconstitution.
What are the most common side effects due to Monjuvi®?
Most common side effects due to Monjuvi® include: decreased appetite, neutropenia, fatigue, anemia, cough, diarrhea, thrombocytopenia, pyrexia, peripheral edema, and respiratory tract infection.
What are the storage conditions of Monjuvi®?
Store refrigerated at 36-46°F (2-8°C) in the original carton in order to protect from light. Neither shake nor freeze it.
How much does Monjuvi® cost in India?
The monjuvi 200 mg cost in India is authentically less and competitive with other medications for DLBCL. In order to procure it, kindly connect to a WHO-GDP & ISO certified pharmaceutical Wholesaler/Distributor/Supplier.
What are the Highlights of prescribing information for Monjuvi®?
Click Here to download full monjuvi prescribing information.
Contact Patient Support
If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
Email Address
Sshealthcare1012@gmail.com
+91 7575883015
Landline
079 48916267
Disclaimer
All Trademarks and Brands that appear on the website belong to their respective owners, and S S Healthcare does not lay any claim on them. We only provide information.
